Chemoprevention in Barrett's oesophagus

Anushka Baruah; Navtej S Buttar

doi:10.1016/j.bpg.2014.12.003

Chemoprevention in Barrett's oesophagus

Best Pract Res Clin Gastroenterol. 2015 Feb;29(1):151-65. doi: 10.1016/j.bpg.2014.12.003. Epub 2014 Dec 29.

Authors

Anushka Baruah¹, Navtej S Buttar²

Affiliations

¹ Mayo Clinic College of Medicine, Department of Gastroenterology and Hepatology, Rochester, MN, USA.
² Mayo Clinic College of Medicine, Department of Gastroenterology and Hepatology, Rochester, MN, USA. Electronic address: buttar.navtej@mayo.edu.

PMID: 25743463
DOI: 10.1016/j.bpg.2014.12.003

Abstract

Increasing incidence of oesophageal adenocarcinoma along with poor survival entails novel preventive strategies. Agents that target pro-oncogenic pathways in Barrett's mucosa could halt this neoplastic transformation. In this review, we will use epidemiological associations and molecular mechanisms to identify novel chemoprevention targets in Barrett's oesophagus. We will also discuss recent chemoprevention trials.

Keywords: Barrett's oesophagus(BO); Chemo-preventive agents; Oesophageal adenocarcinoma(OAC); Surrogate endpoint markers(SEBs).

Publication types

Review

MeSH terms

Adenocarcinoma / epidemiology
Adenocarcinoma / etiology
Adenocarcinoma / prevention & control*
Barrett Esophagus / complications
Barrett Esophagus / drug therapy*
Chemoprevention / methods*
Esophageal Neoplasms / epidemiology
Esophageal Neoplasms / etiology
Esophageal Neoplasms / prevention & control*
Humans
Incidence

Supplementary concepts

Adenocarcinoma Of Esophagus